Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sangamo Therapeutics (SGMO) EPS (Basic) (2016 - 2025)

Sangamo Therapeutics has reported EPS (Basic) over the past 16 years, most recently at -$0.11 for Q4 2025.

  • Quarterly results put EPS (Basic) at -$0.11 for Q4 2025, up 8.33% from a year ago — trailing twelve months through Dec 2025 was -$0.44 (up 15.38% YoY), and the annual figure for FY2025 was -$0.44, up 10.2%.
  • EPS (Basic) for Q4 2025 was -$0.11 at Sangamo Therapeutics, roughly flat from -$0.11 in the prior quarter.
  • Over the last five years, EPS (Basic) for SGMO hit a ceiling of $0.13 in Q1 2023 and a floor of -$0.66 in Q2 2023.
  • Median EPS (Basic) over the past 5 years was -$0.28 (2022), compared with a mean of -$0.25.
  • Biggest five-year swings in EPS (Basic): crashed 3200.0% in 2021 and later surged 143.33% in 2023.
  • Sangamo Therapeutics' EPS (Basic) stood at -$0.25 in 2021, then fell by 28.0% to -$0.32 in 2022, then fell by 6.25% to -$0.34 in 2023, then soared by 64.71% to -$0.12 in 2024, then grew by 8.33% to -$0.11 in 2025.
  • The last three reported values for EPS (Basic) were -$0.11 (Q4 2025), -$0.11 (Q3 2025), and -$0.08 (Q2 2025) per Business Quant data.